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Loss of p53 function is a critical event during tumorigenesis, with half of all cancers harbouring 
mutations within the TP53 gene. Such events frequently result in the expression of a mutated p53 
protein with gain-of-function properties that drive invasion and metastasis. Here, we show that the 
expression of miR-155 was up-regulated by mutant p53 to drive invasion. The miR-155 host gene 
was directly repressed by p63, providing the molecular basis for mutant p53 to drive miR-155 
expression. Significant overlap was observed between miR-155 targets and the molecular profile of 
mutant p53-expressing breast tumors in vivo. A search for cancer-related target genes of miR-155 
revealed ZNF652, a novel zinc finger transcriptional repressor. ZNF652 directly repressed key drivers 
of invasion and metastasis, such as TGFB1, TGFB2, TGFBR2, EGFR, SMAD2 and VIM. Furthermore, 
silencing of ZNF652 in epithelial cancer cell lines promoted invasion into matrigel. Importantly, loss 
of ZNF652 expression in primary breast tumors was significantly correlated with increased local 
invasion and defined a population of breast cancer patients with metastatic tumors. Collectively, 
these findings suggest that miR-155 targeted therapies may provide an attractive approach to treat 











The p53 tumor suppressor is a transcription factor that plays a pivotal role in the prevention 
of neoplastic transformation. Disruption of the p53 pathway is arguably a universal requirement for 
the development of cancer and is ultimately achieved through either direct mutation of the TP53 
gene or indirect inactivation of downstream p53 signalling pathways. However, inactivation of the 
tumor suppressor function of p53 is not the only outcome of a TP53 mutation. Increasing evidence 
suggests that the mutated p53 protein exhibits traits consistent with the acquisition of an oncogenic 
gain-of-function (1, 2). For example, mutations of TP53 gene are frequently missense, involve similar 
codons within the p53 DNA binding domain and are expressed at remarkably high levels in tumor 
cells (1). Somatic TP53 mutations occur in approximately 20% of breast tumors, which in turn define 
a population of particularly aggressive breast lesions associated with a poor prognosis (3, 4). 
 
It is postulated that mutant p53 acquires new oncogenic properties as a result of local or 
global distortion of the protein structure, exposing previously hidden binding interfaces to facilitate 
gain-of-function interactions with novel binding partners. In particular, mutant p53 has been shown 
to acquire the ability to sequester p63 and p73, and this is thought to promote tumor invasion and 
metastasis (5, 6). So what are the key downstream target genes of p63 and p73 that are deregulated 
to promote tumor progression in cancer cells expressing mutant p53? Recent studies have identified 
the metastasis suppressors SHARP1 and cyclin G2 as critical mutant p53 targets that are deregulated 
through loss of p63 signalling (6). The expression of these two genes alone defined a subset of 
particularly aggressive breast tumors associated with poor patient outcome (6). Such examples 
demonstrate the potential utility of targets of mutant p53 as robust clinical prognostic tools and 
therapeutic targets in mutant p53 expressing tumors, however a complete understanding of the 
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mechanisms and pathways exploited by mutant p53 to drive tumorigenesis remain poorly 
understood. A major aspect of the anti-metastatic activity of p63 resides in its ability to regulate 
non-coding RNAs (7) and microRNA processing complexes (8), yet the ability of mutant p53 to 
dysregulate these pathways remains unexplored. We report here that mutant p53 inactivates the 
p63 signalling pathway to up-regulate the expression of an oncogenic microRNA, miR-155. In turn, 
elevated miR-155 levels promote cellular transformation and invasion through the targeting of key 


















miR-155 promotes migration, invasion and amoeboid transformation 
Several microRNAs have been recently implicated in the promotion of tumorigenesis and 
have emerged as potential therapeutic targets. In particular, miR-155 is considered as an oncomiR as 
it is up-regulated in breast tumors (9) and this increased expression is associated with the promotion 
of tumorigenesis (10). To gain a wider appreciation for the role of miR-155 during breast 
tumorigenesis, we measured miR-155 levels in established breast cancer cell lines of epithelial (non-
invasive) and mesenchymal (invasive) origin (11). Indeed, miR-155 was almost absent in epithelial 
lines, but was highly expressed in 4 out of 5 of mesenchymal lines (Supplementary Figure 1), 
suggesting an upregulation of miR-155 during epithelial to mesenchymal transition (EMT) of breast 
cancers. Importantly, this observation was not restricted to breast cancer cell lines, as miR-155 levels 
were absent in the majority of epithelial lines from the NCI-60 panel of cancer cell lines whilst 
showing significantly higher expression in the mesenchymal lines (Figure 1A). To assess whether 
miR-155 can drive EMT in breast tumors, we stably expressed miR-155 in the ZR-75-1 epithelial 
breast cancer cell line. Although present at only modest levels as compared to some mesenchymal 
breast cancer lines (Supplementary Figure 2), exogenous miR-155 dramatically enhanced the ability 
of ZR-75-1 cells to migrate in a scratch-wound assay (Figure 1B). Expression of miR-155 also 
endowed ZR-75-1 cells with a newly acquired ability to invade through matrigel (Figure 1C). 
Interestingly, ZR-75-1 cells expression induced an amoeboid transformation of this epithelial cell 
line, as characterised by the enlarged filamentous cytoplasm with frequent protrusion of 
lamellipodia from these ZR-75-1 cells expressing miR-155 (Figure 1D).  
 
To ensure that these observations were not restricted to the ZR-75-1 cell line, miR-155 was 
also stably expressed in the non-malignant breast epithelial cell line, MCF-10A (Supplementary 
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Figure 2B). Exogenous miR-155 enhanced the ability of MCF-10A cells to migrate (Figure 1B) or 
invade through matrigel (Figure 1C) to similar extents of that observed in ZR-75-1 cells. Although 
miR-155 was able to enhance the frequency of lamellipodia protrusions from MCF-10A cells (Figure 
1D), it did not alter the size of the MCF-10A cells (data not shown). These findings indicate that miR-
155 has general pro-migratory and pro-invasive characteristics in epithelial breast cell lines, however 
the mode of transformation (i.e. amoeboid) may be specific to cell lines.  
 
To examine the altered transcriptional events associated with the miR-155-mediated 
amoeboid transformation and accompanying pro-migratory and invasive characteristics, the 
expression levels of 84 EMT-related genes (see Materials and Methods) were assessed by real-time 
PCR (Figure 1E). Indeed, expression of miR-155 in ZR-75-1 cells was associated with a significant up-
regulation of numerous mesenchymal markers, with the major transcriptional reprogramming by 
miR-155 converging upon the TGF-β signalling pathway. Therefore, we proposed the miR-155 may 
be aberrantly driving the TGF-β signalling pathway in the absence of an exogenous TGF-β ligand. 
Indeed, the addition of exogenous TGF-β to ZR-75-1 cells phenocopied the effects of miR-155 
expression, as characterised by an increased invasive capacity and an amoeboid transformation 
involving enlarged cytoplasm and increased frequency of lamellipodia (Supplementary Figure 3). 
Thus, our findings demonstrate that miR-155 aberrantly stimulates the TGF-β pathway in the 
absence of exogenous TGF-β. 
 
miR-155 is a target microRNA of mutant p53 
Mutant p53 and miR-155 expression are both associated with invasive properties in vivo (2, 
10), which prompted us to investigate whether they promote malignant transformation through a 
similar oncogenic axis. We initially determined if miR-155 can phenocopy mutant p53 in its ability to 
drive invasion and mensenchymal transformation when expressed in the same genetic background. 
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Expression of miR-155 in H1299 cells significantly enhanced their invasive capabilities and drove a 
mesenchymal phenotype with close resemblance to that observed upon induced mutant p53 
expression (Supplementary Figure 4). These observations indicate that miR-155 and mutant p53 may 
drive overlapping oncogenic pathways. Since mutation of TP53 is considered an early event during 
breast tumorigenesis (12, 13), we speculated that miR-155 may be a down-stream target of mutant 
p53 that reprograms the cancer transcriptome to drive invasion and metastasis. Indeed, induced 
expression of either the p53 mutant R248Q or R282W in the p53-null H1299 background was 
associated with a dose-dependent increase in MIR155HG (the precursor transcript for miR-155) 
expression or mature miR-155 levels (Figure 2A). We next examined if endogenous mutant p53 can 
constitutively regulate the expression of miR-155 levels. The mesenchymal breast cancer cell line 
BT549 possesses the highest miR-155 levels of those tested (Supplementary Figure 1) and also 
expresses an endogenous p53 mutant, R249S. Knockdown of this endogenous p53 mutant in BT549 
cells resulted in a significantly reduced level of miR-155 (Figure 2B), confirming a role for mutant p53 
in the aberrant activation of miR-155.  
 
We next examined if miR-155 was up-regulated by mutant p53 in vivo, which was achieved 
through the analysis of a publically available cohort of 100 breast tumors in which both the global 
microRNA expression levels had been profiled and the TP53 gene sequenced. Indeed, miR-155 
expression levels were significantly higher in breast tumors with p53 mutations as compared to 
those breast tumors that had retained wild-type p53 (Figure 2C). Furthermore, miR-155 expression 
was most elevated in the basal breast tumors, the most aggressive breast cancer subtype frequently 
associated with p53 mutations (Figure 2D). Collectively, these observations support the notion of 




miR-155 is directly repressed by p63 
Mutant p53 drives invasion and metastasis through inactivation of targets such as p63 (5, 6), 
ablating the p63 signalling pathways responsible for the suppression of invasion and metastasis. 
Therefore, we examined a role for p63 in the transcriptional control of MIR155HG. In silico analysis 
using the p63Scan software (14) identified a putative p63 response element (RE) in the 3rd exon of 
the MIR155HG gene. Chromatin immunoprecipitation (ChIP) experiments were used to subsequently 
demonstrate that endogenous p63 was directly recruited to this consensus p63-RE in MCF10A, a 
non-malignant breast epithelial cell line (Figure 2E). This association of p63 with the MIR155HG p63-
RE was significantly reduced upon silencing of endogenous p63 in MCF10A cells. Knockdown of p63 
also resulted in a significantly increased expression level of both the MIR155HG transcript and the 
mature miR-155 (Figure 2F). Collectively, these findings indicate that p63 functions as a direct 
transcriptional repressor of miR-155. Previous observations have also shown that miR-155 was 
repressed by wild-type p53, albeit through an unknown mechanism (15). Indeed, induction of wild-
type p53 in H1299 cells repressed MIR155HG expression (Supplementary Figure 5). Our studies 
provide mechanistic insight into this repression, as ChIP experiments demonstrate that this induced 
wild-type p53 protein is also recruited to this newly identified p63-RE located within the MIR155HG 
gene (Figure 2E). These findings suggest a redundancy of function between wild-type p53 and p63 in 
the control of miR-155 expression via transcriptional repression of the precursor MIR155HG 
transcript.  
 
Identification of downstream targets of the miR-155 • mutant p53 axis 
Having established miR-155 as a downstream oncomiR of mutant p53, we sought to identify 
the specific targets of the miR-155 • mutant p53 axis that drive invasion in breast tumors. To obtain 
an understanding of the landscape of miR-155 targets, a comprehensive list of bone fide miR-155 
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targets was collated from the literature (Supplementary Table 1). Selection criteria for these 
published miR-155 target genes included both the demonstration of endogenous transcript 
regulation by miR-155 and validation of the miR-155 seed sequence through a reporter assay. This 
list contains 140 genes and is enriched with known tumor suppressors. Therefore, we speculated 
that mutant p53 may indirectly down-regulate the expression of these genes through aberrant up-
regulation of miR-155. A relationship between the defined miR-155 targets and mutant p53 in breast 
cancer was examined through analysis of publically available transcript profiles of 251 p53-
sequenced primary breast tumors (4). Remarkably, 42 of these 140 miR-155 targets (30%) showed a 
significantly lower expression in breast tumors with mutant p53 compared with tumors with wild 
type p53 (Figure 3A; Supplementary Table 2). These 42 genes can be considered as the key 
downstream targets of the mutant p53 • miR-155 axis and are therefore likely to play critical roles in 
the suppression of breast cancer invasion and metastasis.  
 
The potential of the expression of these 42 genes to predict breast cancer metastasis was 
evaluated through the analysis of a publically available dataset of expression profiling in 78 breast 
tumors (16). Low expression of four genes (ZNF652, PDCD4, TCF12 or IL17RB) was associated with a 
significantly higher frequency of metastasis-related poor outcomes (Figure 3B). This suggests that 
these four miR-155 • mutant p53 targets drive pathways that prevent breast cancer invasion and 
metastasis. ZNF652 was considered an excellent candidate for further investigation as this gene 
encodes a classical zinc-finger DNA binding transcription factor that functions as a transcriptional 







ZNF652 is an epithelial marker and suppresses tumor cell invasion 
Initially we measured ZNF652 transcript and protein levels in breast cancer cell lines, and 
found they are highly expressed in some epithelial cell lines, but are significantly down-regulated in 
mesenchymal cell lines (Figure 4A and B). The expression profile of ZNF652 in these cell lines 
resembles an inverse reflection of their miR-155 expression profiles, which is consistent with 
previous reports demonstrating that miR-155 targets the ZNF652 transcript through a specific seed 
sequence in the 3’UTR (19, 20). Indeed, over-expression of miR-155 markedly reduced endogenous 
ZNF652 protein levels in the H1299 epithelial lung carcinoma cell line (Figure 4C), further 
demonstrating ZNF652 as a miR-155 target. In a wider survey of ZNF652 expression in breast cell 
lines using gene expression microarray data of 51 breast cancer cell lines (21) classified into luminal 
(epithelial) and basal B (mesenchymal) (11), the expression of ZNF652 is highly negatively correlated 
with vimentin expression (r2=0.33, p<0.0001) (Supplementary Figure 6). The luminal (epithelial) cell 
lines have a significantly higher expression of ZNF652 compared with the basal B (mesenchymal) cell 
lines (p<0.0001), while high expression of vimentin is a well known marker of mesenchymal cells. 
These data define ZNF652 as a novel marker for breast epithelial cells and indicate that ZNF652 
expression is down-regulated during mesenchymal transformation, presumably in response to up-
regulation of miR-155. We further examined if the loss of ZNF652 alone is sufficient to drive 
invasion. ZNF652 expression was silenced using a mixture of two specific siRNAs in H1299 cells, and 
their subsequent capacity to invade through matrigel assessed (Figure 4D). Ablation of ZNF652 
expression resulted in a significant increase in the invasive potential of H1299 cells. These data 
indicate that ZNF652 is a key downstream target of the miR-155 • mutant p53 axis that regulates the 





ZNF652 is a master regulator of the EMT gene network 
ZNF652 is a repressor of gene transcription (17), and we hypothesised that this transcription 
factor may suppress invasion and metastasis through constitutive repression of key drivers of 
mesenchymal transformation. Identification of the key ZNF6562 targets will further elucidate the 
downstream regulatory network responsible for metastasis in mutant p53-miR-155 expressing 
breast tumors. We identified putative consensus ZNF652 DNA binding sequences (AnGGGTTAA) (18) 
in the classical promoter region, first intron or 3’ UTR of TGFB1, TGFB2, TGFBR2, EGFR, SMAD2 and 
VIM (Figure 4E). Direct recruitment of endogenous ZNF652 to these gene regulatory elements within 
TGFB1, TGFB2, TGFBR2, EGFR, SMAD2 and VIM was demonstrated through ChIP analysis in ZR-75-1 
cells (Figure 4E), confirming these genes as direct targets of ZNF652. Silencing of ZNF652 expression 
in the ZR-75-1 cell line also resulted in a de-repression of several of these target genes, including 
TGFB1, TGFBR2, EGFR and VIM (Supplementary Figure 7). EMT gene expression profiling (as 
described in Figure 1E) was subsequently performed to assess the global influence of loss of ZNF652 
expression on ZR-75-1 cells. There was considerable overlap between the EMT gene expression 
profiles in response to loss of ZNF652 expression or over-expression of miR-155 (Supplementary 
Figure 8), suggesting that a large proportion of EMT gene regulation by miR-155 may be facilitated 
through its ability to target ZNF652. The identified ZNF652 targets converge upon the TGF-β 
signalling pathway, as was observed for miR-155. Thus, we hypothesize that ZNF652 may suppress 
invasion through repression of the TGF-β signalling pathway. Indeed, forced expression of ZNF652 
ablated the ability of exogenous TGF-β to activate SMAD proteins, as demonstrated using a SMAD 
reporter assay (Supplementary Figure 9).  Collectively, the data suggest that ZNF652 is a master 





ZNF652 suppresses invasion in vivo 
The potential of ZNF652 to suppress invasion in vivo was evaluated in human breast tumors 
by staining tumor microarrays of paraffin embedded formalin fixed tissues with our affinity purified 
polyclonal anti-ZNF652 antibody (Figure 5A). ZNF652 protein levels were assessed in 112 breast 
tumors of known invasive potential, as assessed by the TNM scoring available for each tumor. There 
is a highly significant association of low ZNF652 levels and increased propensity for tumor invasion in 
distant organs or structures (p < 0.001; Fisher exact test), thus demonstrating that ZNF652 is a bone 
fide suppressor of tumor cell dissemination and invasion.  
 
Based on our evidence, we propose that epithelial cancers expressing mutant p53 acquire 
enhanced invasive and metastatic potential through up-regulation of miR-155. This oncomiR drives 
invasion by directly repressing the target transcript ZNF652, which as a consequence causes the de-
repression of a network of EMT genes and acquisition of an invasive cell phenotype (summarised 
diagrammatically in Figure 5B). Collectively, this study provides evidence that miR-155 targeted 
therapies may provide an attractive approach to treat mutant p53 expressing breast tumors. 
Furthermore, histological assessment of the key targets of the mutant p53 • miR-155 axis may have 









miR-155 drives breast cancer cell transformation and invasion 
This study implicates a role for miR-155 in the transformation of the ZR-75-1 and MCF-10A 
epithelial breast cells  (Figure 1). It is of particular interest that miR-155 could impart pro-migratory 
and pro-invasive properties to the non-malignant MCF-10A cell line, as these findings potentially 
indicate that miR-155 possesses transforming capabilities in the breast epithelium. In addition, miR-
155 drove an amoeboid transformation of ZR-75-1 cells. The amoeboid transition of epithelial tumor 
cells represents a major mode of migration and invasion (22). This pro-invasive amoeboid 
transformation was associated with the formation of lamellipodia, which are typically restricted to 
highly mobile and invasive cells (23), properties not frequently associated with the epithelial ZR-75-1 
cell line. Our findings are consistent with the pre-existing notion of miR-155 as a breast cancer 
oncomiR. Previous studies have shown that ectopic expression of miR-155 mimics in the MCF-7 or 
BT-474 breast cancer cell lines was associated with increased proliferation rates (10, 24). 
Furthermore, the ectopic expression of miR-155 mimics in the MDA-MB-231 breast cancer cell line 
accelerated the growth of mammary fat pad tumor xenograft tumors in vivo (10). Our findings 
suggest that these previously observed oncogenic activities of miR-155 in breast cancer cell lines 
result from its ability to rearrange the actin cytoskeleton to reconfigure the cell with a pro-invasive 
morphology (Figure 1).  
 
In contrast to our findings, a previous report suggests that ectopic expression of miR-155 did 
not drive a mesenchymal phenotype in the NMuMG murine mammary epithelial cell line (25). 
Furthermore, ectopic expression of miR-155 had no influence on the proliferation or primary tumor 
growth of 4T1 murine mammary cell lines (26). In fact, findings from Xiang et al suggest that miR-155 
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suppresses the ability of 4T1 cells to undergo EMT. Indeed, it appears that the biological activity of 
miR-155 in human cell lines (10, 24) is vastly different to that observed upon miR-155 expression in 
mammary cell lines that originate from mice (25, 26), suggesting a lack of conservation of miR-155 
seed sequences in its target 3’UTRs across these two species. 
 
The complex regulation of miR-155 expression 
Herein, we demonstrated that either p53 or p63 can directly repress miR-155 levels through 
direct association with the promoter of MIR155HG. As such, a gain-of-function mutation in the TP53 
gene would act as a double-edged sword to activate miR-155 levels through both a loss of wild-type 
p53-mediated repression and also through the inactivation of p63-mediated repression as a result of 
the oncogenic activities of mutant p53 (5, 6). Findings from Adorno et al suggest that the presence of 
TGF-β is a critical factor for mutant p53 to sequester p63 from its target genes. Therefore, it is 
tempting to speculate a role for TGF-β in the regulation of miR-155 expression. This is indeed the 
case, as miR-155 has been previously shown to be upregulated upon TGF-β treatment (25). The 
nature of the relationship between miR-155 and TGF-β is quite complex, as we demonstrated that 
the major transcriptional reprogramming by miR-155 converged upon the TGF-β pathway and 
ectopic expression of miR-155 aberrantly sensitised cells to exogenous TGF-β (Figure 1 and 
Supplementary Figure 3). Collectively, these observations suggest that miR-155 and TGF-β exist in a 
positive feedback loop.  
 
Targets of the mutant p53 • miR-155 axis  
We suggest that ZNF652, PDCD4, TCF12 and IL17RB are critical targets of the mutant p53 • miR-155 
axis in breast cancer (Figure 3), thus implicating them as suppressors of breast cancer invasion and 
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metastasis. Consistent with this hypothesis, PDCD4 has been previously shown to inhibit motility and 
invasion of breast cancer cell lines in vitro (27, 28) and is down-regulated in invasive breast 
carcinomas in vivo (29). Likewise, loss of IL17RB expression is a strong biomarker for clinical outcome 
in breast cancer patients receiving tamoxifen monotherapy (30). Our findings are consistent with a 
similar role for ZNF652 as a suppressor of breast cancer cell invasion. We demonstrate that ZNF652 
directly represses TGFB1, TGFB2, TGFBR2, EGFR, SMAD2 and VIM; genes that have all been 
previously implicated in the promotion of mesenchymal transformation and invasion (6, 31-34). As 
such, we have defined a new role for ZNF652 as a master regulator of the EMT gene network. 
 
In conclusion, we have identified miR-155 as a novel target of mutant p53 • p63 axis. 
Elevated miR-155 levels promote cellular transformation and invasion through the targeting of key 
suppressors of metastasis, such as ZNF652. Collectively, these findings suggest that miR-155 










Materials and Methods 
Cell culture, plasmids and treatments 
H1299 cells were maintained in DMEM supplemented with 10% FBS. ZR-75-1 and BT549 cells were 
maintained in RPMI supplemented with 10% FBS and 1mM sodium pyruvate. H1299 cells with 
inducible expression of wild-type or mutant p53 are as described previously (35). H1299 and ZR-75-1 
were engineered to express either miR-155 or a non-targeting SCR control through retroviral 
mediated transduction with viruses generated by the pMSCV-Puro-GFP-miR-155 or pGIPZ-non-
targeting (Open Biosystems) vectors, followed by selection in 500ng/mL puromycin (Sigma Aldrich, 
Castle Hill, NSW). To silence gene expression in cell lines, cells were transfected with 10 μM of 
various specific siRNA molecules (Qiagen, Doncaster, VIC; listed in Supplementary Table 3) and 
transfected using lipitoid transfection reagent following manufacturer’s protocol (36). For 
constitutive knockdown, the pGIPZ lentiviral shRNAmir system expressing two independent ZNF652-
specific shRNA oligonucleotides (V3LHS_368392 or V2LHS_229362) or a p63-specific shRNA 
oligonucleotides (V2LHS_24250) was used in accordance with the manufacturer’s protocol (Open 
Biosystems, Huntsville, AL).  
 
Immunofluorescence  
Cells were plated at 10% confluence on glass cover slips and grown for 12 days. Where indicated, 
cells were treated with 2ng/mL TGF-β. Media was refreshed every 3 days. For actin staining, media 
was removed from cells followed by 1 × wash with warmed PBS. Cells were fixed with warmed 4% 
PFA for 15 minutes and blocked in 1% BSA/PBS for 20 minutes. Cells were washed in PBS and 
permeabilised for 5 minutes with 0.1% Triton-X/PBS. Phalloidin antibody (diluted 1:500 in 0.1% 
Triton-X/PBS) was added and incubated for 1 hour at room temperature in the dark. Cells were 
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washed 2 × with PBS and mounted in Vectashield mounting medium with DAPI (Vector Laboratories, 
Burlingame, CA). Cells were imaged using Olympus IX70 inverted microscope. 
To score cell size, the major and minor axis of the cells was measured. To score lamellopodia, cells 
with lamellopodia (visualised with actin stain) were counted. Total cell numbers were determined by 
DAPI stain. Analysis was performed using ImageJ software over ≥4 fields of view. A minimum of 100 
cells were counted per condition. 
 
Isolation of RNA, RT-PCR and microRNA analysis 
Briefly, total RNA was extracted from cells using RNeasy mini kit (Qiagen), with quantitative real-
time PCR performed as previously described (37). Specific primers for real-time PCR are listed in 
Supplementary Table 3. Low density PCR arrays of 84 EMT-related genes were performed using the 
Human Epithelial to Mesenchymal Transition RT2Profiler PCR Array System (SABiosciences, Frederick, 
MD) as per manufacturer’s protocol. MiR-155 analysis was performed using the ABI Taqman miRNA 
assay for miR-155, normalising levels to U6, U48 and miR-16 according to the standard protocol. 
 
Western blot analysis and Chromatin Immunoprecipitation (ChIP) 
Western blot and ChIP analysis are described Supplementary Materials and Methods.  
 
Invasion/Migration Assays 
Real-time invasion assays were performed using the xCelligence Real-Time Cell Analyzer (RTCA) DP 
(Roche, Castle Hill, NSW), as per the manufacturer’s protocol. Briefly, sub-confluent cell cultures 
were collected in serum free media and plated at 2×104 cells per well in the top chamber of a CIM-
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Plate 16 pre-coated with 5% matrigel (BD Biosciences). DMEM containing 10% FCS was used as a 
chemo-attractant. Real-time migration assays were performed using Incucyte (Essen, Michigan, 
USA). Phase images were taken every 15 minutes and wound closure and cell confluence calculated 
using specific Incucyte software. 
 
Breast tissue microarrays and immunohistochemistry 
Breast tissue microarrays BR951, BR961 and BR963 were sourced from US Biomax Inc. 
Immunohistochemistry was performed to determine ZNF652 expression. Briefly, slides were heated 
at 50˚C for 2 hours followed by dewaxing 3 × 5 min with xylene, rehydration 3 × 5 min with 100% 
ethanol and 2 × 3 min with PBS. Slides were subsequently treated with 1:100 dilution H2O2 in PBS for 
5 min at RT followed by 2 × 3 min wash in PBS. Slides were immersed in citrate buffer and 
microwaved on high for 3 min (until boiling) followed by 15 min on low. Cooled slides were washed 2 
× 3 min in PBS. Slides were blocked in 5% rabbit serum in PBS at RT for 30 min and incubated with an 
affinity purified rabbit polyclonal antibody against ZNF652 (17) overnight at 4˚C. Slides were washed 
2 × 3 min in PBS followed by addition of biotinylated rabbit specific secondary antibody (Dako 
Australia, Cambellfield, VIC) at 1:400 in blocking solution and incubated for 1 hr at RT in a humid 
chamber. Streptavidin (1:500 dilution in PBS) was added and incubated for 1 hr at RT in a humid 
chamber. DAB and H2O2 solutions were added and incubated at RT for 6 min. Sections were 
counterstained with Lillie-Mayer haematoxylin for 15-30 sec, washed once with water and 
dehydrated through 3 × 5 min washes 100% ethanol and 3 × 5 min washes with xylene. Slides were 
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Figure 1. miR-155 expression drives invasion in ZR-75-1 and MCF-10A cells 
A. The relative expression levels of miR-155 were determined in the NCI-60 panel. Cell lines 
were classified as epithelial and mesenchymal based on the E-cadherin / vimentin protein 
ratio (38).   
B. The ability of ZR-75-1 cells (control or miR-155) or MCF-10A cells (control or miR-155) to 
migrate was determined by a scratch-wound assay using Incucyte (Essen). Phase images 
were taken every 120 minutes and relative wound width was calculated in real-time using 
Incucyte software. 
C. ZR-75-1 cells (control or miR-155) or MCF-10A cells (control or miR-155) were plated in the 
upper chamber of a CIM-16 plate coated with 5% matrigel. Invasion was measured in real-
time using an xCelligence RTCA DP analyser. 
D. ZR-75-1 cells (control or miR-155) or MCF-10A cells (control or miR-155) were seeded at 10% 
confluence and grown for 12 days. Cells were stained for F-actin using a phalloidin antibody, 
with lamellopodia and cell size scored as described in Materials and Methods. 
Representative images of ZR-75-1 cells (control or miR-155) are shown. 
E. The expression of EMT related genes in ZR-75-1 cells expressing miR-155 was determined 
using a low density PCR array. Data are presented as a fold change in expression relative to 
ZR-75-1 expressing a scrambled RNA sequence (control). Data presented is an average of 
three independent biological replicates. 
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Figure 2. miR-155 expression is regulated by p63 
A. H1299 inducible p53-R248Q or p53-R282W cells were treated with 2.5 μg/mL PonA for 0, 24, 
48 or 72 hours to induce either p53 R248Q or p53 R282W protein expression. Relative 
MIR155HG expression levels or mature miR-155 levels were determined by specific RT-PCR. 
Induction of p53 R248Q and p53 R282W proteins were determined by Western blot analysis. 
B. Endogenous mutant p53 (R249S) expression was silenced by transient transfection of a 
specific siRNA targeting p53 (see Materials and Methods). Relative miR-155 expression was 
determined by an ABI Taqman miRNA assay. Knockdown of endogenous p53 R249S was 
confirmed by Western blot analysis. 
C. The expression levels of miR-155 and p53 status of a cohort of 100 breast tumors were 
derived from a publically available dataset (GSE19536).  
D. Publically available gene expression profiling of the cohort of 100 breast tumors from (C) 
was used to segregate the cases into breast cancer subtypes. The expression levels of miR-
155 was significantly different across the subtypes, as determined using a 1-way ANOVA. 
E. DNA-p63 complexes were immunoprecipitated from MCF-10A cell lysates using a p63 
antibody (or IgG control) and normalised against two unrelated genomic regions (see 
Materials and Methods). Fold enrichment of a putative p63-RE within the MIR155HG gene 
(as compared to IgG control) was determined. The anti-p63 antibody (H-129) detects both 
the TAp63 and Np63 isoforms. The ability of p53 to bind this response element was 
determined in H1299 cells upon induction of wild-type p53 protein. Fold enrichment of p53 
within this region of the MIR155HG gene was determined by ChIP analysis following 
induction of p53-WT in EI H1299 cells for 24 hours. 
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F. Endogenous p63 was silenced in MCF-10A cells through constitutive lentiviral-mediated 
expression of a specific shRNA targeting the p63 transcript (left panel). Relative expression 
levels of MIR155HG or mature miR-155 were determined by specific RT-PCR in MCF10A cells 
expressing p63-specific shRNA (which targets both the TAp63 and Np63 isoforms) or a non-
targeting control shRNA (as above).  Knockdown of p63 expression was confirmed by real-
time PCR (using primers that detect both the TAp63 and Np63 isoforms) or through 




Figure 3. Four genes commonly regulated by the mutant p53•miR-155 axis are associated with 
poor metastasis-free survival 
A. Of the 140 published miR-155 target genes (see Supplementary Table 1), the expression of 
42 of these genes was significantly correlated with mutant p53 status in vivo (4). Loss of 
expression of 4 of these 42 genes predict metastasis in vivo, as determined from a publicly 
available dataset of 78 breast tumors (16).  
B. Kaplan-Meier plots derived from publically available survival data associated with a cohort of 
78 breast tumors with metastasis-free survival data (16). Expression of ZNF652, PCDC4, 
TCF12 and IL7RB was sourced from expression microarray analyses. Tumors were ranked for 
gene expression, with those tumors below the median expression level of the cohort defined 
as ‘Low Expression’ and those tumors above the median expression level of the cohort 




Figure 4. ZNF652 is an epithelial cell marker which is down-regulated in EMT by miR-155 
A. Nuclear extracts from a panel of epithelial and mesenchymal breast cancer cell lines were 
screened for ZNF652 protein expression with a specific polyclonal anti-ZNF652 antibody 
(Kumar, 2006). Equal loading was determined by Lamin A/C. 
B. Relative mRNA expression of ZNF652 was determined in a panel of cell lines by specific RT-
PCR. 
C. ZNF652 protein levels were determined in H1299 cells following constitutive expression of 
miR-155 (described and characterised in Supplementary Figure 4). 
D. Knockdown of ZNF652 expression using a 50:50 mixture of two specific siRNA 
oligonucleotides in H1299 resulted in an enhanced ability of H1299 cells to invade into 
matrigel, as determined in real-time using an xCelligence RTCA DP analyser. ZNF652 
transcript levels were determined by real-time PCR following siRNA-mediated knockdown 
for 48 hours. 
E. In silico screening of the classical promoter regions (10kB upstream), first introns and 3’UTRs 
of TGFB1, TGFB2, TGFBR2, EGFR, SMAD2 and VIM identified multiple putative ZNF652 
binding sites (BS), as illustrated in schematic diagram. ChIP analysis was performed in ZR-75-
1 cells using a specific ZNF652 antibody, with the fold-enrichment of ZNF652 bound at each 
putative ZNF652 binding site determined relative to an IgG control and normalised against 






Figure 5. Loss of ZNF652 expression is associated with increased tumor invasion in vivo 
A. Immunohistochemistry was performed on breast tissue microarrays to determine ZNF652 
expression in vivo. ZNF652 expression was significantly associated (* indicates p<0.001, 
Fisher exact test) with tissue invasion as assessed by the TNM staging (where ‘low’, 
‘medium’ or ‘high’ indicates T2, T3 or T4 classifications, respectively) as defined by the 
American Joint Committee on Cancer. Tissues were classified as low ZNF652 expression 
when there was negligible staining of 95% of the breast tumor nuclei. 
B. Schematic diagram representing the proposed mechanism of mutant p53 driving EMT and 
tumor cell invasion through a pathway involving miR-155 and ZNF652. 
